AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35584530 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) experience during cystoscopy
Number of subjects: 159
Study 35584530 — intervention group
Group type: COMPARATOR
Intervention: Control group (no VR experience)
Number of subjects: 159
Study 33653754 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration therapy coupled with protocolised mobilisation
Number of subjects: 188
Study 33653754 — intervention group
Group type: COMPARATOR
Intervention: Protocolised mobilisation alone
Number of subjects: 188
Study 32024955 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotically controlled Eperisone 150 mg tablets
Number of subjects: 12
Study 32024955 — intervention group
Group type: COMPARATOR
Intervention: Immediate release Eperisone tablets (reference formulation)
Number of subjects: 12
Study 34567486 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention
Number of subjects: 0
Study 34567486 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing intervention
Number of subjects: 0
Study 33239951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 9
Study 33239951 — intervention group
Group type: COMPARATOR
Intervention: Active Recovery (AR)
Number of subjects: 9
Study 33239951 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 9
Study 34691212 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (25 mg orally 3 times a day for 90 days)
Number of subjects: 44
Study 34691212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 34327587 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 250
Study 34327587 — intervention group
Group type: EXPERIMENTAL
Intervention: Diseased individuals
Number of subjects: 250
Study 34327587 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural individuals
Number of subjects: 250
Study 34327587 — intervention group
Group type: COMPARATOR
Intervention: Urban individuals
Number of subjects: 250
Study 34327587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample randomization algorithm
Number of subjects: 250
Study 32599738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal A (0% whole grain flour, high sugar content, 24 g/100 g)
Number of subjects: 46
Study 32599738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal B (50% whole grain flour, medium sugar content, 12 g/100 g)
Number of subjects: 46
Study 33795476 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverages
Number of subjects: 121
Study 33795476 — intervention group
Group type: COMPARATOR
Intervention: Soda water
Number of subjects: 121
Study 32777383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin treatment for 24 weeks
Number of subjects: 290
Study 32777383 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 24 weeks
Number of subjects: 290
Study 35412654 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer application to the perianal area
Number of subjects: 118
Study 35412654 — intervention group
Group type: COMPARATOR
Intervention: Care without application of moisturizer to the perianal area
Number of subjects: 118
Study 35412654 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer application
Number of subjects: 118
Study 32680742 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy (information booklet and 30-minute face-to-face session with a physiotherapist)
Number of subjects: 441
Study 32680742 — intervention group
Group type: COMPARATOR
Intervention: Control group (information booklet only)
Number of subjects: 441
Study 35981270 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (modified folinic acid-fluorouracil-oxaliplatin 6 or capecitabine-oxaliplatin) for 3 months followed by transanal excision surgery (TES)
Number of subjects: 58
Study 35981270 — intervention group
Group type: COMPARATOR
Intervention: Observation after declining TME surgery
Number of subjects: 58
Study 35981270 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal excision surgery (TES) after chemotherapy
Number of subjects: 58
Study 35981270 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year locoregional relapse-free survival
Number of subjects: 58
Study 35981270 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year locoregional relapse-free survival
Number of subjects: 58
Study 35981270 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life and rectal function scores
Number of subjects: 58
Study 34086194 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) refeeding protocol of 20 kcal/kg/day, reaching energy goals within 3 days
Number of subjects: 85
Study 34086194 — intervention group
Group type: COMPARATOR
Intervention: Cautious refeeding protocol of 10 kcal/kg/day, reaching goals within 7 days
Number of subjects: 85
Study 32187464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care
Number of subjects: 199
Study 32187464 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 199
Study 36242050 — intervention group
Group type: EXPERIMENTAL
Intervention: Revitive Medic© Program 1
Number of subjects: 3
Study 36242050 — intervention group
Group type: EXPERIMENTAL
Intervention: Revitive® Program 2
Number of subjects: 3
Study 36242050 — intervention group
Group type: COMPARATOR
Intervention: Revitive sham
Number of subjects: 3
Study 34772742 — intervention group
Group type: EXPERIMENTAL
Intervention: Editorial intervention to reduce spin in the abstract's conclusion of manuscripts
Number of subjects: 0
Study 34772742 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32558330 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypocaloric Mediterranean diet
Number of subjects: 87
Study 32558330 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard paediatric recommendations)
Number of subjects: 87
Study 36471427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous computerised anaesthesia (ICA) using QuickSleeper™ system
Number of subjects: 72
Study 36471427 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block anaesthesia (IANB)
Number of subjects: 72
Study 36245373 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO-PVS severity (moderate or frequent/severe)
Number of subjects: 0
Study 36245373 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO-PVS (moderate or frequent/severe)
Number of subjects: 0
Study 36245373 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO-PVS and time (follow-up)
Number of subjects: 0
Study 35465733 — intervention group
Group type: EXPERIMENTAL
Intervention: alpelisib + trastuzumab (HR-negative cohort)
Number of subjects: 300
Study 35465733 — intervention group
Group type: EXPERIMENTAL
Intervention: alpelisib + trastuzumab + fulvestrant (HR-positive cohort)
Number of subjects: 300
Study 35465733 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab + chemotherapy (eribuline, capecitabine or vinorelbine)
Number of subjects: 300
Study 34582451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF) plus anti-infective therapies (azithromycin, more frequent IPTp, testing/treatment for vaginal dysbiosis)
Number of subjects: 1489
Study 34582451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF) plus anti-infective therapies
Number of subjects: 1489
Study 34582451 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (blended corn/soy flour and intermittent preventive treatment for malaria in pregnancy)
Number of subjects: 1489
Study 34582451 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1489
Study 35956410 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone nutrition intervention
Number of subjects: 111
Study 35956410 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application nutrition intervention
Number of subjects: 111
Study 35956410 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 111
Study 34753153 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 88
Study 34753153 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 88
Study 2010656616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate-sealed Donati technique (group A)
Number of subjects: 90
Study 2010656616 — intervention group
Group type: COMPARATOR
Intervention: Intracutaneous running technique without seal (group B)
Number of subjects: 90
Study 34110272 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC with 5-min delay (IPC5)
Number of subjects: 12
Study 34110272 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC with 45-min delay (IPC45)
Number of subjects: 12
Study 34110272 — intervention group
Group type: COMPARATOR
Intervention: SHAM with 5-min delay (SHAM5)
Number of subjects: 12
Study 34110272 — intervention group
Group type: COMPARATOR
Intervention: SHAM with 45-min delay (SHAM45)
Number of subjects: 12
Study 32216723 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Carbamide gel
Number of subjects: 0
Study 32216723 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide gel
Number of subjects: 0
Study 32216723 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching systems
Number of subjects: 0
Study 32259647 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision tinted lenses (optimal colour of light)
Number of subjects: 14
Study 32259647 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision tinted lenses (different CIE UCS chromaticity by 0.077)
Number of subjects: 14
Study 32259647 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 matched children without ASD)
Number of subjects: 14
Study 33556381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL) 2 mg at baseline and every 4 weeks thereafter
Number of subjects: 105
Study 33556381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL) treat‐and‐extend phase
Number of subjects: 105
Study 33556381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVT‐AFL)
Number of subjects: 105
Study 33264163 — intervention group
Group type: EXPERIMENTAL
Intervention: SVOP
Number of subjects: 97
Study 33264163 — intervention group
Group type: COMPARATOR
Intervention: SAP
Number of subjects: 97
Study 35685522 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 154
Study 35685522 — intervention group
Group type: COMPARATOR
Intervention: Low-fat high-carbohydrate diet (LF-HC)
Number of subjects: 154
Study 35685522 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular diet)
Number of subjects: 154
Study 32597741 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ (Food Frequency Questionnaire)
Number of subjects: 254
Study 35745116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Oral Nutritional Supplement (LC-ONS)
Number of subjects: 20
Study 35745116 — intervention group
Group type: COMPARATOR
Intervention: Standard Oral Nutritional Supplement (ST-ONS)
Number of subjects: 20
Study 35922824 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting prolonged air leak (PAL) after minimally invasive pulmonary resection
Number of subjects: 2213
Study 33399934 — intervention group
Group type: EXPERIMENTAL
Intervention: novel adjuvant dendritic cell therapy with transfection of heat-shock protein 70 messenger RNA
Number of subjects: 0
Study 33399934 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32783912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for peanut allergies
Number of subjects: 0
Study 35472391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest BNP decline
Number of subjects: 4133
Study 35472391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest NT-proBNP decline
Number of subjects: 4133
Study 35472391 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastest hematocrit increase
Number of subjects: 4133
Study 33183969 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-palliating treatment
Number of subjects: 179
Study 33183969 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-based treatments or guideline-based treatments in combination with non-guideline-based treatments
Number of subjects: 179
Study 33183969 — intervention group
Group type: COMPARATOR
Intervention: Overall treatment (guideline based or non-guideline based)
Number of subjects: 179
Study 32645162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) regimens including nucleoside/nucleotide reverse‐transcriptase inhibitor (NRTI) plus nonnucleoside reverse‐transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus protease inhibitor (19%).
Number of subjects: 7770
Study 32645162 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry ART regimens varied by Global Burden of Disease (GBD) region.
Number of subjects: 7770
Study 33459079 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-managed computer therapy
Number of subjects: 11
Study 34490707 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg once daily
Number of subjects: 60
Study 34490707 — intervention group
Group type: COMPARATOR
Intervention: Clofazimine 100 mg thrice daily
Number of subjects: 60
Study 34490707 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 60
Study 34490707 — intervention group
Group type: COMPARATOR
Intervention: Clofazimine
Number of subjects: 60
Study 35685595 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occlusion combined with uterine artery embolization
Number of subjects: 38
Study 35685595 — intervention group
Group type: COMPARATOR
Intervention: Conventional cesarean section
Number of subjects: 38
Study 34789340 — intervention group
Group type: EXPERIMENTAL
Intervention: GlycaCare‐II
Number of subjects: 69
Study 35608183 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide and dexamethasone (EloRd)
Number of subjects: 319
Study 34706415 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion-escitalopram
Number of subjects: 143
Study 34706415 — intervention group
Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 143
Study 34706415 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine-mirtazapine
Number of subjects: 143
Study 36403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose febuxostat (20 mg/day)
Number of subjects: 120
Study 36403976 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (200 mg/day)
Number of subjects: 120
Study 36403976 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose febuxostat
Number of subjects: 120
Study 36403976 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 120
Study 33449480 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopatch testing using the photoallergen series
Number of subjects: 70
Study 33449480 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine sensitization via oral exposure
Number of subjects: 70
Study 33449480 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopatch testing
Number of subjects: 70
Study 32596393 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides from Tripterygium wilfordii Hook F (TwHF) combined with angiotensin receptor blocker (ARB)
Number of subjects: 70
Study 32596393 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blocker (ARB) only
Number of subjects: 70
Study 35649713 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation ON (n=8)
Number of subjects: 18
Study 35649713 — intervention group
Group type: COMPARATOR
Intervention: Stimulation OFF (n=10)
Number of subjects: 18
Study 34044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard syphilis self‐testing (SST) delivery arm
Number of subjects: 300
Study 34044760 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral link SST delivery arm
Number of subjects: 300
Study 34044760 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 300
Study 32762649 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-tolerant genotype Y12-4
Number of subjects: 2
Study 32762649 — intervention group
Group type: COMPARATOR
Intervention: Cold-sensitive genotype ce 253
Number of subjects: 2
Study 32762649 — intervention group
Group type: EXPERIMENTAL
Intervention: LTG5 gene overexpression
Number of subjects: 2
Study 35899486 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling with topical irradiated amniotic collagen matrix (IACM)
Number of subjects: 20
Study 35899486 — intervention group
Group type: COMPARATOR
Intervention: Microneedling with topical platelet rich plasma (PRP)
Number of subjects: 20
Study 32000167 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Number of subjects: 53
Study 32000167 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemotherapy (fluorouracil, leucovorin calcium, doxorubicin, cyclophosphamides/granulocyte colony-stimulating factor)
Number of subjects: 53
Study 32289385 — intervention group
Group type: EXPERIMENTAL
Intervention: Germicidal wipes
Number of subjects: 0
Study 32289385 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet (UV) irradiation
Number of subjects: 0
Study 32289385 — intervention group
Group type: COMPARATOR
Intervention: No routine cleaning
Number of subjects: 0
Study 35305667 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor®G2 (chlorfenapyr and alpha‐cypermethrin)
Number of subjects: 750
Study 35305667 — intervention group
Group type: EXPERIMENTAL
Intervention: Royal Guard® (pyriproxyfen and alpha‐cypermethrin)
Number of subjects: 750
Study 35305667 — intervention group
Group type: EXPERIMENTAL
Intervention: Olyset™ Plus (piperonyl butoxide and permethrin)
Number of subjects: 750
Study 35305667 — intervention group
Group type: COMPARATOR
Intervention: Interceptor® (alpha‐cypermethrin only)
Number of subjects: 750
Study 34210360 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CBDV
Number of subjects: 28
Study 34210360 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 28
Study 36002368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib
Number of subjects: 0
Study 36002368 — intervention group
Group type: EXPERIMENTAL
Intervention: Lazertinib + SBRT
Number of subjects: 0
Study 34337046 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-immune gene signature
Number of subjects: 0
Study 34337046 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-related nomogram
Number of subjects: 0
Study 35383073 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy
Number of subjects: 1290
Study 35383073 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy
Number of subjects: 1290
Study 35383073 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy
Number of subjects: 1290
Study 35715757 — intervention group
Group type: EXPERIMENTAL
Intervention: High pitch auditory feedback (150-250 Hz)
Number of subjects: 32
Study 35715757 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pitch auditory feedback (95-112 Hz)
Number of subjects: 32
Study 35715757 — intervention group
Group type: EXPERIMENTAL
Intervention: Right quiet condition
Number of subjects: 32
Study 35715757 — intervention group
Group type: EXPERIMENTAL
Intervention: Left quiet condition
Number of subjects: 32
Study 32050061 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stents
Number of subjects: 1996
Study 32050061 — intervention group
Group type: COMPARATOR
Intervention: Polymer-free drug-coated stents
Number of subjects: 1996
Study 36331805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4h time in bed)
Number of subjects: 53
Study 36331805 — intervention group
Group type: COMPARATOR
Intervention: Typical sleep (8h time in bed)
Number of subjects: 53
Study 33563279 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual education on information literacy delivered in six modules over four weeks
Number of subjects: 79
Study 33563279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no virtual education)
Number of subjects: 79
Study 33818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy, perceived collective efficacy, concerns about invasive plants, social norms
Number of subjects: 2600
Study 33818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Past experience talking to others or working with neighbors
Number of subjects: 2600
Study 33818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived need for collective action
Number of subjects: 2600
Study 33818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms
Number of subjects: 2600
Study 33818641 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about invasive plants on neighboring or nearby properties
Number of subjects: 2600
Study 33818641 — intervention group
Group type: COMPARATOR
Intervention: Socio-demographic characteristics (age, gender, education level, income) and land ownership characteristics (residence status, having a written forest management plan)
Number of subjects: 2600
Study 32613718 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (1000 IU/day)
Number of subjects: 201
Study 35584529 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol solution
Number of subjects: 0
Study 35584529 — intervention group
Group type: COMPARATOR
Intervention: Sodium Picosulfate with Magnesium Oxide
Number of subjects: 0
Study 33864832 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 50% MIP for 4 weeks
Number of subjects: 12
Study 33864832 — intervention group
Group type: COMPARATOR
Intervention: Sham group at 5% MIP for 4 weeks
Number of subjects: 12
Study 33864832 — intervention group
Group type: EXPERIMENTAL
Intervention: After 4 weeks of detraining from IMT
Number of subjects: 12
Study 32829105 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation
Number of subjects: 213
Study 32829105 — intervention group
Group type: COMPARATOR
Intervention: Conventional biweekly FOLFIRI plus bevacizumab without UGT1A1 genotyping
Number of subjects: 213
Study 32829105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation of irinotecan based on UGT1A1 genotyping
Number of subjects: 213